{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:56:39Z","timestamp":1793861799069,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016003","name":"Mie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We analyzed the impact of the diagnosis-to-treatment interval (DTI) on survival in patients with CD5-positive diffuse large B-cell lymphoma (CD5\u2009+\u2009DLBCL), using a data set of newly diagnosed patients. Among the 336 eligible patients, 247 (74%) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), and 89 (26%) were treated with dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The median DTI was 18\u00a0days (range 0\u2013118). The short DTI (\u2264\u200914\u00a0days) group included 135 patients (40%), and the long DTI (&gt;\u200914\u00a0days) group included 201 patients (60%). Compared with the long DTI group, the short DTI group had more aggressive disease characteristics. Both the progression-free survival (PFS) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and the overall survival (OS) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) were significantly inferior in the short DTI group compared with those in the long DTI group. Among 89 patients who received DA-EPOCH-R, no significant differences in PFS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.92) or OS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.86) were observed between the two groups. Multivariate analysis revealed that no DA-EPOCH-R was a risk factor for PFS in the short DTI group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.06). A short DTI was a negative prognostic factor in our CD5\u2009+\u2009DLBCL cohort. DA-EPOCH-R could be considered a potential treatment option for patients with a short DTI.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07021-0","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T03:02:07Z","timestamp":1777086127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-4556","authenticated-orcid":false,"given":"Yuma","family":"Nato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6547-3181","authenticated-orcid":false,"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiju","family":"Negoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Masunari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Tawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-6489","authenticated-orcid":false,"given":"Motoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"7021_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood.V99.3.815","volume":"99","author":"M Yamaguchi","year":"2002","unstructured":"Yamaguchi M, Seto M, Okamoto M (2002) De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815\u2013821","journal-title":"Blood"},{"key":"7021_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3324\/haematol.12810","volume":"93","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Nakamura N, Suzuki R et al (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195\u20131202","journal-title":"Haematologica"},{"key":"7021_CR3","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International agency for research on cancer, Lyon, France"},{"key":"7021_CR4","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","volume":"22","author":"K Miyazaki","year":"2011","unstructured":"Miyazaki K, Yamaguchi M, Suzuki R et al (2011) CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22:1601\u20131607","journal-title":"Ann Oncol"},{"key":"7021_CR5","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.18632\/oncotarget.3479","volume":"6","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette ZY, Tu M, Jabbar KJ et al (2015) Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 6:5615\u20135633","journal-title":"Oncotarget"},{"key":"7021_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1349-7006.2006.00267.x","volume":"97","author":"M Suguro","year":"2006","unstructured":"Suguro M, Tagawa H, Kagami Y et al (2006) Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci 97:868\u2013874","journal-title":"Cancer Sci"},{"key":"7021_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12185-015-1812-2","volume":"102","author":"K Miyazaki","year":"2015","unstructured":"Miyazaki K, Yamaguchi M, Imai H et al (2015) Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression. Int J Hematol 102:188\u2013194","journal-title":"Int J Hematol"},{"key":"7021_CR8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/cncr.30404","volume":"123","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T, Yamaguchi M, Kobayashi K et al (2017) MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer 123:1166\u20131173","journal-title":"Cancer"},{"key":"7021_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/bjh.17765","volume":"195","author":"T Mishina","year":"2021","unstructured":"Mishina T, Oshima-Hasegawa N, Tsukamoto S et al (2021) Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort. Br J Haematol 195:731\u2013742","journal-title":"Br J Haematol"},{"key":"7021_CR10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/annonc\/mdn392","volume":"19","author":"D Ennishi","year":"2008","unstructured":"Ennishi D, Takeuchi K, Yokoyama M et al (2008) CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 19:1921\u20131926","journal-title":"Ann Oncol"},{"key":"7021_CR11","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1182\/blood-2008-09-177469","volume":"113","author":"NA Johnson","year":"2009","unstructured":"Johnson NA, Boyle M, Bashashati A et al (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 113:3773\u20133780","journal-title":"Blood"},{"key":"7021_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hon.896","volume":"28","author":"R Hyo","year":"2010","unstructured":"Hyo R, Tomita N, Takeuchi K et al (2010) The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol 28:27\u201332","journal-title":"Hematol Oncol"},{"key":"7021_CR13","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","volume":"117","author":"G Salles","year":"2011","unstructured":"Salles G, de Jong D, Xie W et al (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117:7070\u20137078","journal-title":"Blood"},{"key":"7021_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00428-015-1845-1","volume":"467","author":"WY Chuang","year":"2015","unstructured":"Chuang WY, Chang H, Shih LY et al (2015) CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch 467:571\u2013582","journal-title":"Virchows Arch"},{"key":"7021_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ajh.24299","volume":"91","author":"L Alinari","year":"2016","unstructured":"Alinari L, Gru A, Quinion C et al (2016) De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol 91:395\u2013399","journal-title":"Am J Hematol"},{"key":"7021_CR16","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3324\/haematol.2019.231076","volume":"105","author":"K Miyazaki","year":"2020","unstructured":"Miyazaki K, Asano N, Yamada T et al (2020) DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica 105:2308\u20132315","journal-title":"Haematologica"},{"key":"7021_CR17","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1111\/cas.15784","volume":"114","author":"K Miyazaki","year":"2023","unstructured":"Miyazaki K, Sakai R, Iwaki N et al (2023) Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer Sci 114:2689\u20132691","journal-title":"Cancer Sci"},{"key":"7021_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70047","volume":"43","author":"Y Nato","year":"2025","unstructured":"Nato Y, Miyazaki K, Maruyama D et al (2025) Treatments and outcomes of newly diagnosed CD5-positive diffuse large B-cell lymphoma: a multi-institutional observational study. Hematol Oncol 43:e70047","journal-title":"Hematol Oncol"},{"key":"7021_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjh.15224","volume":"181","author":"AJ Olszewski","year":"2018","unstructured":"Olszewski AJ, Ollila T, Reagan JL (2018) Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol 181:495\u2013504","journal-title":"Br J Haematol"},{"key":"7021_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/hon.2977","volume":"40","author":"K Miyazaki","year":"2022","unstructured":"Miyazaki K, Suzuki R, Oguchi M et al (2022) Long-term outcomes and central nervous system relapse in extranodal natural killer\/T-cell lymphoma. Hematol Oncol 40:667\u2013677","journal-title":"Hematol Oncol"},{"key":"7021_CR21","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK et al (2018) Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 36:1603\u20131610","journal-title":"J Clin Oncol"},{"key":"7021_CR22","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM et al (2021) Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol 39:2605\u20132616","journal-title":"J Clin Oncol"},{"key":"7021_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2020.7654","volume":"19","author":"DN Blunt","year":"2021","unstructured":"Blunt DN, Smyth L, Nagamuthu C et al (2021) Shorter diagnosis-to-treatment interval in diffuse large B-cell lymphoma is associated with inferior overall survival in a large, population-based registry. J Natl Compr Canc Netw 19:719\u2013725","journal-title":"J Natl Compr Canc Netw"},{"key":"7021_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82615-4","volume":"11","author":"M Yoshida","year":"2021","unstructured":"Yoshida M, Nakaya Y, Shimizu K et al (2021) Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma. Sci Rep 11:2837","journal-title":"Sci Rep"},{"key":"7021_CR25","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.clml.2024.09.012","volume":"25","author":"J Allen","year":"2025","unstructured":"Allen J, Abbott D, Eskandar J et al (2025) DA-R-EPOCH may mitigate the adverse prognostic implication of the diagnosis-to-treatment interval (DTI) in large B-cell lymphomas. Clin Lymphoma Myeloma Leuk 25:e26\u2013e33","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"7021_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000448389","volume":"60","author":"I Cozzolino","year":"2016","unstructured":"Cozzolino I, Rocco M, Villani G, Picardi M (2016) Lymph node fine-needle cytology of non-Hodgkin lymphoma: diagnosis and classification by flow cytometry. Acta Cytol 60:302\u2013314","journal-title":"Acta Cytol"},{"key":"7021_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/dc.21127","volume":"37","author":"I Cozzolino","year":"2009","unstructured":"Cozzolino I, Nappa S, Picardi M et al (2009) Clonal B-cell population in a reactive lymph node in acquired immunodeficiency syndrome. Diagn Cytopathol 37:910\u2013914","journal-title":"Diagn Cytopathol"},{"key":"7021_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ajcp\/aqz145","volume":"153","author":"A Travaglino","year":"2020","unstructured":"Travaglino A, Pace M, Varricchio S et al (2020) Hashimoto thyroiditis in primary thyroid non-Hodgkin lymphoma. Am J Clin Pathol 153:156\u2013164","journal-title":"Am J Clin Pathol"},{"key":"7021_CR29","first-page":"2493","volume":"141","author":"W Alduaij","year":"2023","unstructured":"Alduaij W, Collinge B, Ben-Neriah S et al (2023) Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood 141:2493\u20132507","journal-title":"Blood"},{"key":"7021_CR30","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","volume":"5","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Fanale MA, Abramson JS et al (2018) Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 5:e609\u2013e617","journal-title":"Lancet Haematol"},{"key":"7021_CR31","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH et al (2019) Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303. J Clin Oncol 37:1790\u20131799","journal-title":"J Clin Oncol"},{"key":"7021_CR32","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"MC Zhang","year":"2023","unstructured":"Zhang MC, Tian S, Fu D et al (2023) Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell 41:1705\u20131716.e1705","journal-title":"Cancer Cell"},{"key":"7021_CR33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1200\/JCO.23.01574","volume":"42","author":"A Cooper","year":"2024","unstructured":"Cooper A, Tumuluru S, Kissick K et al (2024) CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Bruton\u2019s tyrosine kinase inhibition. J Clin Oncol 42:467\u2013480","journal-title":"J Clin Oncol"},{"key":"7021_CR34","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial. J Clin Oncol 41:2238\u20132247","journal-title":"J Clin Oncol"},{"key":"7021_CR35","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","volume":"404","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Ku M, Hertzberg M et al (2024) Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet 404:1940\u20131954","journal-title":"Lancet"},{"key":"7021_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351\u2013363","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07021-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:42:18Z","timestamp":1781649738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07021-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7021"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07021-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.N. reports grants from AbbVie, AstraZeneca, Chugai, Eisai, Genmab, Incyte, Kyowa Kirin, Otsuka, Sumitomo and Takeda and honoraria from AbbVie and Chugai. K.M. reports grants from Takeda, Otsuka, Chugai, Sumitomo, Kyowa Kirin, AstraZeneca, Genmab, Incyte, AbbVie, SymBio and Zenyaku and honoraria from Chugai, SymBio, Janssen, Nippon Shinyaku, AstraZeneca, BMS, Meiji Seika, AbbVie, Novartis, Incyte, Asahi Kasei, Ono, Kyowa Kirin, Daiichi Sankyo, Gilead Sciences, Takeda and Genmab. D.M. reports grants from Kyowa Kirin, Novartis, Chugai, Ono, Takeda, Janssen, Sanofi, Otsuka, BMS, Astellas, Eisai, AbbVie, Taiho, MSD, Pfizer, AstraZeneca, Genmab, SymBio and Zenyaku and honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai, Kyowa Kirin, MSD, Zenyaku, Sanofi, SymBio, Takeda, AbbVie, BMS, Genmab, Novartis and AstraZeneca. H.T. reports honoraria from Chugai. K.S. reports grants from AbbVie, Incyte, GSK, Sanofi, Novartis, Pfizer, BMS, Janssen, BeiGene, Kyowa Kirin, Ono, Otsuka, Chugai and Tanabe and honoraria from BMS, Sanofi, Pfizer and Janssen. E.N. reports honoraria from Nippon Kayaku. N.Takayama reports grants from Chugai and honoraria from AbbVie and Janssen. Y.K. reports honoraria from AbbVie and Novartis. M.N. reports grants from SymBio and Japanese society of hematology and honoraria from Chugai and Genmab. N.Takahashi reports honoraria from AstraZeneca, Janssen, Asahi Kasei, Eisai, Kyowa Kirin, Takeda, Ono, Nippon Kayaku, Chugai, Ohara, Daiichi Sankyo and AbbVie. T.Masunari reports honoraria from Nippon Shinyaku, Eisai, BMS, Novartis, AstraZeneca, Takeda, Janssen, GSK, MSD, Gilead Sciences, Chugai, Daiichi Sankyo, BeOne, Minophagen, Ohara, Kyowa Kirin, AbbVie, Sanofi, Genmab, Meiji Seika, Ono, Kissei, Pfizer, Otsuka, Amgen, Incyte, Nippon Kayaku, Nihon Servier, Astellas, and Tanabe. J.T. reports grants from AstraZeneca, AbbVie and Tanabe and honoraria from AstraZeneca and Janssen. K.I. reports grants from AstraZeneca, AbbVie, Incyte, BMS, Novartis, Daiichi Sankyo, Chugai, Beigene, Genmab, LOXO Oncology and Regeneron. K.K. reports grants from BMS, Gilead Sciences, Chugai, AbbVie, Daiichi Sankyo, Novartis and Ono and honoraria from Gilead Sciences, Chugai and AbbVie. M.Yamaguchi reports grants from AstraZeneca, Chugai, Genmab, Incyte, AbbVie and SymBio; consulting fees from BeOne, Genmab and Nihon Servier; and honoraria from AbbVie, BeOne, BMS, Chugai, Daiichi Sankyo, Eisai, Genmab, Janssen, Kyowa Kirin, Meiji Seika, MSD, Nihon Servier, SymBio and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}